MX2023002108A - Compuestos como agonistas de glp-1r. - Google Patents
Compuestos como agonistas de glp-1r.Info
- Publication number
- MX2023002108A MX2023002108A MX2023002108A MX2023002108A MX2023002108A MX 2023002108 A MX2023002108 A MX 2023002108A MX 2023002108 A MX2023002108 A MX 2023002108A MX 2023002108 A MX2023002108 A MX 2023002108A MX 2023002108 A MX2023002108 A MX 2023002108A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- glp
- agonists
- tautomers
- stereoisomers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063068870P | 2020-08-21 | 2020-08-21 | |
| PCT/US2021/047015 WO2022040600A1 (en) | 2020-08-21 | 2021-08-20 | Compounds as glp-1r agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002108A true MX2023002108A (es) | 2023-07-11 |
Family
ID=80350630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002108A MX2023002108A (es) | 2020-08-21 | 2021-08-20 | Compuestos como agonistas de glp-1r. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20230322744A1 (https=) |
| EP (1) | EP4199919A4 (https=) |
| JP (1) | JP2023538408A (https=) |
| KR (1) | KR20230074486A (https=) |
| CN (1) | CN116507326A (https=) |
| AU (1) | AU2021327397A1 (https=) |
| BR (1) | BR112023003168A2 (https=) |
| CA (1) | CA3192601A1 (https=) |
| CL (2) | CL2023000516A1 (https=) |
| CO (1) | CO2023003322A2 (https=) |
| IL (1) | IL300795A (https=) |
| MX (1) | MX2023002108A (https=) |
| PE (1) | PE20231206A1 (https=) |
| TW (1) | TWI905252B (https=) |
| WO (1) | WO2022040600A1 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4048664A1 (en) | 2019-10-25 | 2022-08-31 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| ES3016132T3 (en) | 2020-01-29 | 2025-05-08 | Gilead Sciences Inc | Glp-1r modulating compounds |
| TW202206429A (zh) | 2020-04-29 | 2022-02-16 | 美商迦舒布魯姆生物有限公司 | 雜環ｇｌｐ—１促效劑 |
| JP2023537501A (ja) | 2020-08-06 | 2023-09-01 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| EP4204415A4 (en) | 2020-08-28 | 2025-03-26 | Gasherbrum Bio, Inc. | HETEROCYCLIC GLP-1 AGONISTS |
| CA3188891A1 (en) | 2020-09-01 | 2022-01-13 | Fanglong Yang | Fused imidazole derivative, preparation method therefor, and medical use thereof |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| CR20230330A (es) * | 2021-01-28 | 2023-11-15 | Carmot Therapeutics Inc | Agonistas del receptor gpcr, composiciones farmaceuticas que los comprenden y métodos para su uso |
| WO2022184849A1 (en) * | 2021-03-04 | 2022-09-09 | Les Laboratoires Servier | Glp-1r agonists, uses and pharmaceutical compositions thereof |
| WO2022192428A1 (en) * | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| EP4304712A1 (en) * | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| US20240208952A1 (en) * | 2021-03-22 | 2024-06-27 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Thiophene glp-1 receptor agonist and use thereof |
| JP7772778B2 (ja) * | 2021-03-24 | 2025-11-18 | 塩野義製薬株式会社 | 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物 |
| CN117222631A (zh) * | 2021-03-24 | 2023-12-12 | 诚益生物(美国)公司 | 苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-苯基-、苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-杂芳基-或苯基-[1,3]二氧杂环戊烯并[4,5-c]吡啶基-哌啶基-甲基-氧杂环丁烷基甲基-1h-苯并[d]咪唑-甲酸衍生物及其使用方法 |
| IL306110A (en) | 2021-04-21 | 2023-11-01 | Gilead Sciences Inc | Carboxy-benzimidazole glp-1r modulating compounds |
| TWI843104B (zh) | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| WO2023011539A1 (zh) * | 2021-08-04 | 2023-02-09 | 上海翰森生物医药科技有限公司 | 环烯类衍生物调节剂、其制备方法和应用 |
| US20240374587A1 (en) | 2021-09-08 | 2024-11-14 | Shionogi & Co., Ltd. | Medicine for prevention and treatment of diseases linked to anti-obesity activity |
| PT4408840T (pt) | 2021-09-27 | 2025-10-07 | Terns Pharmaceuticals Inc | Ácidos benzimidazolocarboxílicos como agonistas de glp-1r |
| US20250115612A1 (en) | 2021-10-05 | 2025-04-10 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4-b]pyrazines as glp-1 receptor modulators |
| WO2023057414A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| MX2024004131A (es) | 2021-10-05 | 2024-04-22 | Astrazeneca Ab | Ciertos 2,5-diazabiciclo[4.2.0]octanos como moduladores del receptor de glp-1. |
| CN118401519A (zh) | 2021-10-25 | 2024-07-26 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| US20250042882A1 (en) | 2021-12-16 | 2025-02-06 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| WO2023111144A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| CN119095843A (zh) | 2022-02-23 | 2024-12-06 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| US20250214968A1 (en) * | 2022-03-25 | 2025-07-03 | Ildong Pharmaceutical Co., Ltd. | Novel Salt of GLP-1 Receptor Agonist Compound, Preparation Method Thereof and Pharmaceutical Composition Comprising Thereof |
| US20250136584A1 (en) * | 2022-05-20 | 2025-05-01 | Chengdu Di'ao Jiuhong Pharmaceutical Factory | Benzimidazole Or Azabenzimidazole Compound, Preparation Method Therefor And Use Thereof |
| CN120289354A (zh) * | 2022-07-18 | 2025-07-11 | 厦门市博瑞来医药科技有限公司 | 五元并六元化合物、其中间体、制备方法、组合物和应用 |
| JPWO2024063140A1 (https=) * | 2022-09-22 | 2024-03-28 | ||
| EP4592285A1 (en) | 2022-09-22 | 2025-07-30 | Shionogi & Co., Ltd. | Fused ring compound having glp-1 receptor agonist effect |
| CN116102543B (zh) * | 2022-10-21 | 2025-07-22 | 江南大学 | 一种glp-1r激动剂、合成方法及其用途 |
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| KR20250085816A (ko) | 2022-11-16 | 2025-06-12 | 일라이 릴리 앤드 캄파니 | 글루카곤-유사 펩티드 1 수용체 효능제 |
| TW202434574A (zh) * | 2023-02-02 | 2024-09-01 | 大陸商江蘇豪森藥業集團有限公司 | 一種環烯類化合物的鹽、晶型及其製備方法和應用 |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
| WO2024212742A1 (zh) * | 2023-04-10 | 2024-10-17 | 上海研健新药研发有限公司 | 一种glp-1r激动剂，其制备方法和应用 |
| CN120981457A (zh) | 2023-09-14 | 2025-11-18 | 歌礼制药(中国)有限公司 | Glp-1r激动剂及其治疗方法 |
| TW202515865A (zh) * | 2023-09-21 | 2025-04-16 | 南韓商尹諾衛醫藥有限公司 | 製備取代的稠合咪唑衍生物的方法 |
| TW202521534A (zh) | 2023-11-24 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102314286B1 (ko) * | 2016-12-16 | 2021-10-21 | 화이자 인코포레이티드 | Glp-1 수용체 작용제 및 이의 용도 |
| DK3806855T5 (da) * | 2018-06-15 | 2023-05-22 | Pfizer | GLP-1-receptoragonister og anvendelser deraf |
| US11254660B2 (en) * | 2018-08-31 | 2022-02-22 | Pfizer Inc. | Combinations for treatment of NASH/NAFLD and related diseases |
| MA54555A (fr) * | 2018-11-22 | 2021-09-29 | Qilu Regor Therapeutics Inc | Agonistes de glp-1r et leurs utilisations |
| WO2021096284A1 (ko) * | 2019-11-15 | 2021-05-20 | 일동제약(주) | Glp-1 수용체 작용제 및 이의 용도 |
| EP4334304A1 (en) * | 2021-05-03 | 2024-03-13 | Carmot Therapeutics, Inc. | Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| CN117715906A (zh) * | 2021-07-21 | 2024-03-15 | 和博医药有限公司 | 胰高血糖素样肽-1受体调节剂及其用途 |
-
2021
- 2021-08-20 CA CA3192601A patent/CA3192601A1/en active Pending
- 2021-08-20 JP JP2023512462A patent/JP2023538408A/ja active Pending
- 2021-08-20 TW TW110130936A patent/TWI905252B/zh active
- 2021-08-20 PE PE2023000511A patent/PE20231206A1/es unknown
- 2021-08-20 MX MX2023002108A patent/MX2023002108A/es unknown
- 2021-08-20 AU AU2021327397A patent/AU2021327397A1/en active Pending
- 2021-08-20 US US18/042,443 patent/US20230322744A1/en active Pending
- 2021-08-20 US US17/445,588 patent/US20220089578A1/en not_active Abandoned
- 2021-08-20 KR KR1020237009681A patent/KR20230074486A/ko not_active Withdrawn
- 2021-08-20 BR BR112023003168A patent/BR112023003168A2/pt unknown
- 2021-08-20 CN CN202180071858.5A patent/CN116507326A/zh active Pending
- 2021-08-20 EP EP21859247.5A patent/EP4199919A4/en active Pending
- 2021-08-20 WO PCT/US2021/047015 patent/WO2022040600A1/en not_active Ceased
- 2021-08-20 IL IL300795A patent/IL300795A/en unknown
-
2023
- 2023-02-21 CL CL2023000516A patent/CL2023000516A1/es unknown
- 2023-03-17 CO CONC2023/0003322A patent/CO2023003322A2/es unknown
-
2024
- 2024-04-05 CL CL2024001025A patent/CL2024001025A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230322744A1 (en) | 2023-10-12 |
| CO2023003322A2 (es) | 2023-07-10 |
| TWI905252B (zh) | 2025-11-21 |
| WO2022040600A1 (en) | 2022-02-24 |
| AU2021327397A9 (en) | 2024-08-08 |
| IL300795A (en) | 2023-04-01 |
| KR20230074486A (ko) | 2023-05-30 |
| EP4199919A1 (en) | 2023-06-28 |
| EP4199919A4 (en) | 2024-12-25 |
| JP2023538408A (ja) | 2023-09-07 |
| CN116507326A (zh) | 2023-07-28 |
| TW202227410A (zh) | 2022-07-16 |
| US20220089578A1 (en) | 2022-03-24 |
| CL2024001025A1 (es) | 2024-10-04 |
| BR112023003168A2 (pt) | 2023-05-09 |
| CL2023000516A1 (es) | 2023-10-30 |
| CA3192601A1 (en) | 2022-02-24 |
| AU2021327397A1 (en) | 2023-05-04 |
| PE20231206A1 (es) | 2023-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023002108A (es) | Compuestos como agonistas de glp-1r. | |
| MX2024010346A (es) | Compuestos como agonistas de glp-1r. | |
| MX2024003872A (es) | Acidos carboxilicos de benzimidazol como agonistas de glp-1r. | |
| MX2023006186A (es) | Derivado de benzimidazol y método de preparación del mismo y uso médico del mismo. | |
| MX2022009524A (es) | Agonistas heterociclicos de glp-1. | |
| MX2023001311A (es) | Agonistas heterociclicos de glp-1. | |
| MX2025009636A (es) | Agonistas heterocíclicos de glp-1 | |
| SA521431209B1 (ar) | مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1 | |
| ZA202306748B (en) | Glp-1r receptor agonist compound and use thereof | |
| PH12023550130A1 (en) | Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same | |
| CR20230330A (es) | Agonistas del receptor gpcr, composiciones farmaceuticas que los comprenden y métodos para su uso | |
| ZA202100208B (en) | Heterocyclic and heteroaryl compounds for treating huntington's disease | |
| MX2020000268A (es) | Agonista de fxr. | |
| MY209614A (en) | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents | |
| MX2023004149A (es) | Degradadores de moléculas pequeñas de piperidinilo de helios y procedimientos de uso. | |
| ECSP22092977A (es) | Antagonista del receptor crf1 para el tratamiento de la hiperplasia suprarrenal congénita | |
| DOP2004000907A (es) | Procedimientos y composiciones farmaceuticas para tratar aterosclerosis dislipidemias y afecciones relacionadas | |
| WO2012112626A3 (en) | Compositions, devices and methods of use thereof for the treatment of cancers | |
| JOP20250110A1 (ar) | ناهضات مستقبل الببتيد الشبيه بالجلوكاجون-1 | |
| EP4623929A3 (en) | Compositions for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis | |
| EP4272823A3 (en) | Pharmaceutical composition for treating sarcopenia comprising glucagon-like peptide-1 receptor agonist | |
| MX2021007455A (es) | Composicion farmaceutica para el tratamiento de hipertension arterial pulmonar. | |
| NO20080552L (no) | GLP-1 farmasoytiske sammensetninger | |
| MX2025000641A (es) | Composiciones y métodos para el tratamiento del trastorno metabólico y el hígado | |
| ZA202400228B (en) | Combination therapies for treatment of liver diseases |